Replies to post #202711 on NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Longfellow95,

I found this:

First published March 8, 2018

“Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial”

Bruno Francois,1,2,3 Robin Jeannet,2 Thomas Daix,1,2 Andrew H. Walton,4 Matthew S. Shotwell,5 Jacqueline Unsinger,4 Guillaume Monneret,6,7 Thomas Rimmelé,7,8 Teresa Blood,4 Michel Morre,9 Anne Gregoire,9 Gail A. Mayo,10 Jane Blood,4 Scott K. Durum,11 Edward R. Sherwood,10,12 and Richard S. Hotchkiss4,13,14

FUNDING. Revimmune, NIH National Institute of General Medical Sciences GM44118.
Conflict of interest: M. Morre and A. Gregoire are Revimmune employees.
https://insight.jci.org/articles/view/98960#FN

Anne Grégoire
Director Process Development
Company Name Revimmune
Dates Employed Jun 2014 – Present
Employment Duration 4 yrs 7 mos
Location Paris Area, France

Interests- Following Companies: Toucan Capital, Northwest Biotherapeutics, Cognate Bioservices, ……
https://www.linkedin.com/in/anne-grégoire-86639b57/

Michel MORRE

Chief Science Officer chez REVIMMUNE

https://www.linkedin.com/in/michel-morre-7b6556153/?originalSubdomain=be

Interleukin 7 - Revimmune SAS
Alternative Names: CYT 107; Glycosylated recombinant human interleukin-7 - Cytheris; IL-7; Recombinant human interleukin-7 - Cytheris; rhIL-7; Second-generation CYT 99 007
Latest Information Update: 19 Sep 2018

https://adisinsight.springer.com/drugs/800020133

[Lykiri]

AV is good at ferreting out ancient history, and he might comment from his own perspective.

Funny!